Disease oriented treatment of metastatic colorectal cancer (CRC) with dose-dense 5-FU/Folinic acid (FU/FA) combination chemotherapy

被引：0
|
作者：
Loeffler, TM [1 ]
Droege, C [1 ]
Lenfers, BHM [1 ]
Hausamen, TU [1 ]
机构：
[1] Stadt Kliniken Dortmund, Dept Med, Dortmund, Germany
来源：
EUROPEAN JOURNAL OF CANCER | 1999年 / 35卷
关键词：
D O I：
10.1016/S0959-8049(99)80661-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
228
引用
收藏
页码：S73 / S73
页数：1
相关论文
共 50 条
  • [31] Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in second and third-line treatment of metastatic colorectal cancer (mCRC): Safety and efficacy analysis.
    Smith, D. M.
    Legoux, J.
    Brunet, R.
    Adhoute, X.
    Blanc, J.
    Fonck, M.
    Vendrely, V.
    Becouarn, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 160S - 160S
  • [32] COMBINATION CHEMOTHERAPY OF ADVANCED COLORECTAL CANCER IN PATIENTS PREVIOUSLY TREATED WITH 5-FU
    MOAYERI, H
    EVANS, JT
    MITTELMAN, A
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1978, 19 (MAR): : 323 - 323
  • [33] FIRST LINE CHEMOTHERAPY (FLC) USING OXALIPLATIN, 5-FLUOROURACIL (5-FU) AND FOLINIC ACID (FA) (FOLFOX-4) COMBINED WITH BEVACIZUMAB IN METASTATIC COLORECTAL CANCER (MCRC)
    Gluzman, A.
    Fridman, J.
    Lazarev, I
    Man, S.
    Walfish, S.
    Ariad, S.
    Lavrenkov, K.
    ANNALS OF ONCOLOGY, 2009, 20 : 66 - 66
  • [34] A comparison of dose and scheduling effect of 5-FU chemotherapy in advanced colorectal cancer
    O'Neill, PA
    Smith, DB
    Marshall, E
    Clark, PI
    O'Reilly, SM
    BRITISH JOURNAL OF CANCER, 2001, 85 : 44 - 44
  • [35] Retrospective comparative analysis of 5FU plus low-dose folinic acid vs 5FU plus high-dose folinic acid in the treatment of metastatic colorectal cancer - The Ottawa experience
    Maroun, JA
    Cripps, C
    Goel, R
    Dahrouge, S
    Boisvert, D
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1997, 20 (04): : 387 - 392
  • [36] THE STATUS OF 5-FU AND FOLINIC ACID (FA, RESCUVOLIN(R)) IN THE TREATMENT CONCEPT OF NONRESECTABLE COLORECTAL LIVER METASTASES - A COMPARISON OF 5-FU/FA IA VS 5-FU/FA IV VS 5-FUDR IA VS 5-FUDR IA+IV IN AN OBSERVATION STUDY
    LINK, KH
    KREUSER, ED
    SAFI, F
    ULLRICH, J
    SCHALHORN, A
    SCHMOLL, E
    BEGER, HG
    TUMORDIAGNOSTIK & THERAPIE, 1993, 14 (06) : 224 - 231
  • [37] High-dose chronomodulated infusion of 5-fluorouracil (5-FU) and folinic acid (FA) (FF5-16) in advanced colorectal cancer patients
    Terzoli, E
    Garufi, C
    Zappalà, AR
    Vanni, B
    Pugliese, P
    Cappellini, GA
    Aschelter, AM
    Perrone, M
    Giannarelli, D
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2004, 130 (08) : 445 - 452
  • [38] Suramin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in metastatic colorectal cancer patients resistant to 5-FU+LV-based chemotherapy
    Falcone, A
    Pfanner, E
    Brunetti, I
    Allegrini, G
    Lencioni, M
    Galli, C
    Masi, G
    Danesi, D
    Antonuzzo, A
    Del Tacca, M
    Conte, PF
    TUMORI, 1998, 84 (06) : 666 - 668
  • [39] High-dose chronomodulated infusion of 5-fluorouracil (5-FU) and folinic acid (FA) (FF5–16) in advanced colorectal cancer patients
    Edmondo Terzoli
    Carlo Garufi
    Albina Rita Zappalà
    Barbara Vanni
    Patrizia Pugliese
    Giancarlo Antonini Cappellini
    Anna Maria Aschelter
    Maria Perrone
    Diana Giannarelli
    Journal of Cancer Research and Clinical Oncology, 2004, 130 : 445 - 452
  • [40] Adjuvant chemotherapy of Dukes C colon carcinoma: Comparison of 5-FU plus levamisole (LEV) 12 months vs. 5-FU plus folinic acid (FA) 12 months VS 5-FU plus FA 6 months
    Hartung, G
    Maas, K
    Edler, L
    Diezler, P
    Hagmuller, E
    Pasternak, L
    Queisser, W
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 751 - 751
12345